INVESTOR ALERT: Levi & Korsinsky, LLP Announces Investigation of Idenix Pharmaceuticals, Inc. & Its Board of Directors In Con...
10 Juin 2014 - 5:50PM
Business Wire
Levi & Korsinsky is investigating the Board of Directors of
Idenix Pharmaceuticals, Inc. (“Idenix” or “the Company”) (Nasdaq:
IDIX) for possible breaches of fiduciary duty and other violations
of state law in connection with the sale of the Company to Merck
(NYSE: MRK).
Click here to learn more about the investigation:
http://zlk.9nl.com/idenix-pharmaceuticals-idix, or call:
877-363-5972. There is no cost or obligation to you.
Under the terms of the transaction, Idenix shareholders will
receive $24.50 in cash for each share of Idenix stock they own,
representing a total approximate transaction value of $3.85
billion. The investigation concerns whether the Board of Idenix
breached their fiduciary duties to stockholders by failing to
adequately shop the Company before agreeing to enter into this
transaction, and whether Merck is underpaying for Idenix
shares.
If you own Idenix common stock and wish to obtain additional
information, please contact Joseph E. Levi, Esq. either via email
at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free:
(877) 363-5972, or visit
http://zlk.9nl.com/idenix-pharmaceuticals-idix.
Levi & Korsinsky is a national firm with offices in New
York, New Jersey, Connecticut and Washington D.C. The firm’s 26
attorneys have extensive expertise in prosecuting securities
litigation involving financial fraud, representing investors
throughout the nation in securities and shareholder lawsuits. For
more information, please feel free to contact any of the attorneys
listed below. Attorney advertising. Prior results do not guarantee
similar outcomes.
Levi & Korsinsky, LLPJoseph Levi, Esq.Eduard Korsinsky,
Esq.Tel: 212-363-7500Toll Free: 877-363-5972Fax:
866-367-6510www.zlk.com
(MM) (NASDAQ:IDIX)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
(MM) (NASDAQ:IDIX)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about (MM) (NASDAQ): 0 recent articles
Plus d'articles sur Idenix Pharmaceuticals, Inc. (MM)